Orphanet: Essais cliniques

Rechercher un essai clinique

Autre(s) option(s) de recherche

156 Résultat(s)

Essai(s) clinique(s) national(aux)

A Phase II, multicenter, randomized, double-blind study of LY2157299 monohydrate monotherapy or LY2157299 monohydrate Plus Lomustine therapy compared to Lomustine monotherapy in patients with recurrent Glioblastoma - DE Neurologische Universitätsklinik Heidelberg Abteilung für Neuroonkologie

NOA-20/Improvement of functional outcome for patients with newly diagnosed grade II or III glioma with co-deletion of 1p/19q - IMPROVE CODEL Neurologische Universitätsklinik Heidelberg Abteilung für Neuroonkologie

An open-label, Phase I/II multicenter clinical trial of VXM01 in combination with avelumab in patients with progressive glioblastoma following standard treatment with or without second surgery Neurologische Universitätsklinik Heidelberg Abteilung für Neuroonkologie

GERAS: Effect of Timing of Tumor-Treating Fields Plus Short-Course Radiation in Elderly Patients With Glioblastoma Neurologische Universitätsklinik Heidelberg Klinik für Radioonkologie und Strahlentherapie

Evaluation of the Feasibility of PD L 506 for Stereotactic Interstitial Photodynamic Therapy (iPDT) in Adult Patients With Newly Diagnosed Supratentorial IDH Wild-type Glioblastoma LMU Klinikum der Universität München - Campus Großhadern Neurochirurgische Klinik und Poliklinik

CAR2BRAIN: Single Center, Open Label, Phase I Study of Intracranial Injection of NK-92/5.28.z (HER2.taNK) Cells in Patients With Recurrent HER2-positive Glioblastoma Institution: Information not provided - DE

Autologous Dendritic Cells and Metronomic Cyclophosphamide for Relapsed High-Grade Gliomas in Children and Adolescents Universitätsmedizin Göttingen Klinik für Kinder- und Jugendmedizin

GLORIA: Single-arm, Dose-Escalation, Phase 1/2 Study of Olaptesed Pegol (NOX-A12) in Combination with Irradiation in Inoperable or Partially Resected First-line Glioblastoma Patients with Unmethylated MGMT Promoter Universitätsklinikum Bonn (AöR) Klinik und Poliklinik für Neurologie

MecMeth: Phase I/II study of meclofenamate/temozolomide combination therapy for relapsed MGMT promoter-methylated glioblastoma. Universitätsklinikum Bonn (AöR) Klinik und Poliklinik für Neurologie

Phase II trial of vaccination with lysate-loaded, mature dendritic cells integrated into standard radiochemotherapy in newly diagnosed glioblastoma -DE- Universitätsklinikum Düsseldorf Klinik für Neurochirurgie

GLORIA: Single-arm, Dose-Escalation, Phase 1/2 Study of Olaptesed Pegol (NOX-A12) in Combination with Irradiation in Inoperable or Partially Resected First-line Glioblastoma Patients with Unmethylated MGMT Promoter Universitätsklinikum Essen Klinik für Neurologie

PriCoTTF - PriCoTTF Study: A phase I/II study with TTFields before and during radiotherapy in newly diagnosed glioblastoma Westdeutsches Tumorzentrum Essen (WTZ) Klinik für Innere Medizin (Tumorforschung)

MIRAGE: A Phase III Trial of Marizomib in Combination With Standard Temozolomide-based Radiochemotherapy Versus Standard Temozolomide-based Radiochemotherapy Alone in Patients With Newly Diagnosed Glioblastoma - AT Institution: Information not provided - AT

TRIDENT EF-32: Pivotal, Randomized, Open-Label Study of Optune® (Tumor Treating Fields, 200kHz) Concomitant With Radiation Therapy and Temozolomide for the Treatment of Newly Diagnosed Glioblastoma - AT Institution: Information not provided - AT

GBM AGILE: Global Adaptive Trial Master Protocol: An International, Seamless Phase II/III Response Adaptive Randomization Platform Trial Designed To Evaluate Multiple Regimens In Newly Diagnosed and Recurrent GBM - AT Institution: Information not provided - AT

ADDIT-GLIO: Adjuvant Dendritic-Cell Immunotherapy Plus Temozolomide Following Surgery and Chemoradiation in Patients With Newly Diagnosed Glioblastoma Antwerp University Hospital - UZA Antwerp University Hospital

DOSINDYGO: Etude de Phase II multicentrique avec escalade de dose-lumière, de la thérapie photodynamique peropératoire du glioblastome - BE Cliniques Universitaires de Bruxelles - Hôpital Erasme Service de Neurologie

Etude de phase IIb visant à évaluer l'efficacité d'un traitement du glioblastome / gliosarcome par la suppression de la voie PI3K / Akt par rapport à la MK-3475 (Pembrolizumab) Cliniques universitaires Saint-Luc - UCLouvain Cliniques Universitaires Saint-Luc

A Randomized Phase II Clinical Trial on the Efficacy of Axitinib as a Monotherapy or in Combination With Lomustine for the Treatment of Patients With Recurrent Glioblastoma Universitair Ziekenhuis Brussel NMRC Site UZBrussel

Phase II Clinical Trial on the Combination of Avelumab and Axitinib for the Treatment of Patients With Recurrent Glioblastoma Universitair Ziekenhuis Brussel Universitair Ziekenhuis Brussel (UZ Brussel)

SonoFIRST: Multisite Open-label Randomized Phase II Clinical Trial in Newly Diagnosed Glioblastoma Treated by Concurrent Temoradiation and Adjuvant Temozolomide +/- Ultrasound-induced Blood Brain Barrier Opening - BE UZ Leuven - Campus Gasthuisberg Dienst Neurochirurgie

A Phase 2 clinical study of pomalidomide (CC-4047) monotherapy for children and young adults with recurrent or progressive primary brain tumors -ES Institution: Information not provided - ES

A Phase 1b, Open-label, Dose-Finding Study of CC-90010 in Combination With Temozolomide With or Without Radiation Therapy in Subjects With Newly Diagnosed Glioblastoma - ES Institution: Information not provided - ES

ROSALIE: A MulticenteR, Open-Label, First-in-Human, PhaSe Ib/IIa Trial of EO2401, a Novel Multipeptide Therapeutic VAccine, with and without PD-1 Check Point Inhibitor, FoLlowing Standard Treatment in PatIents with ProgrEssive Glioblastoma - ES Institution: Information not provided - ES

MIRAGE: A phase III trial of marizomib in combination with standard temozolomide-based radiochemotherapy versus standard temozolomide-based radiochemotherapy alone in patients with newly diagnosed glioblastoma - ES Institution: Information not provided - ES

A Phase Ib Dose Finding Study Assessing Safety and Activity of [177Lu]Lu-DOTA-TATE in Newly Diagnosed Glioblastoma in Combination With Radiotherapy With or Without Temozolomide and in Recurrent Glioblastoma as Single Agent -ES Institution: Information not provided - ES

A Phase 1 Study to Investigate the Safety, Pharmacokinetics, and Efficacy of Tinostamustine, a Novel Alkylating and Deacetylase Inhibiting Molecule, as Adjuvant Treatment in Patients with Newly Diagnosed Unmethylated MGMT-promoter Glioblastoma -ES Institution: Information not provided - ES

INDIGO: A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study of AG-881 in Subjects With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation - ES Institution: Information not provided - ES

GLINERA: Pilot safety study of neoadjuvant radiotherapy in patients with glioblastoma - ES Hospital Clínico San Carlos Servicio de Neurocirugía

GEINOGLAS: Phase Ib/II Multicentric Study Combining Glasdegib with temozolomide in patients with newly diagnosed Glioblastoma, safety and preliminary efficacy for the combination - ES Hospital Universitario Ramón y Cajal Servicio de Oncología Médica

A Phase I Study of Cytosine Deaminase-Expressing Neural Stem Cells in Combination With Oral 5-Fluorocytosine and Leucovorin for the Treatment of Recurrent High-Grade Gliomas - US City of Hope City of Hope National Medical Center

A Phase 2, Investigator Initiated Study to Determine the Safety and Efficacy of TH-302 in Combination With Bevacizumab for Glioblastoma Following Bevacizumab Failure - US University of Texas Health Science Center

A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC Versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma Institution: Information not provided - US

A Phase II, Multi-center, Open-label Study of a Conditionally Replicative Adenovirus (DNX-2401) With Pembrolizumab (KEYTRUDA®) for Recurrent Glioblastoma or Gliosarcoma (CAPTIVE/KEYNOTE-192) Institution: Information not provided - US

A Phase 2 Trial of High-Dose Ascorbate in Glioblastoma Multiforme Institution: Information not provided - US

Vaccine Therapy for the Treatment of Newly Diagnosed Glioblastoma Multiforme Institution: Information not provided - US

Anti-LAG-3 or Urelumab Alone and in Combination With Nivolumab in Treating Patients With Recurrent Glioblastoma Institution: Information not provided - US

Qualitative, Qualitative, and Functional Studies Over the First Year in Measuring Immune System Response During the First Year of Therapy in Patients With Brain Tumors Institution: Information not provided - US

Tremelimumab and Durvalumab in Combination or Alone in Treating Patients With Recurrent Malignant Glioma Institution: Information not provided - US

Bevacizumab and Ascorbic Acid in Patients Treating With Recurrent High Grade Glioma Institution: Information not provided - US

Cediranib Maleate and Olaparib Compared to Bevacizumab in Treating Patients With Recurrent Glioblastoma Institution: Information not provided - US

Radiation Therapy Plus Temozolomide and Pembrolizumab With and Without HSPPC-96 in Newly Diagnosed Glioblastoma (GBM) Institution: Information not provided - US

NU-0129 in Treating Patients With Recurrent Glioblastoma or Gliosarcoma Undergoing Surgery Institution: Information not provided - US

Pembrolizumab and Standard Therapy in Treating Patients With Glioblastoma Institution: Information not provided - US

Ferumoxytol MRI in Assessing Response to Pembrolizumab in Patients With Brain Tumors From Melanoma and Glioblastoma Institution: Information not provided - US

Randomized, Prospective, Multicenter Blinding Singles With Arm A and Arm B Innovative Strategy Strategy Conventional (Phase III) - FR CHU de Lyon HCL - GH Est-Hôpital Neurologique P. Wertheimer Service de neurochirurgie tumorale - chirurgie des malformations vasculaires du systéme nerveux

GLYRad : Etude de phase I/II testant l'association du LY2228820 à une radiochimiothérapie avec TMZ concomitant chez des patients présentant un glioblastome nouvellement diagnostiqué CLCC Jean Perrin

Phase Ib/II Multicenter Study of Buparlisib Plus Carboplatin or Lomustine in Patients With Recurrent Glioblastoma Multiforme (Phase I and II) - FR Institution: Information not provided - FR

A Phase 2, Multicenter, Open-label Study of BGJ398 in Patients With Recurrent Resectable or Unresectable Glioblastoma (Phase II) - FR Institution: Information not provided - FR

NANO-GBM: Étude de phase I/II des nanoparticules AGuIX avec radiothérapie plus témozolomide concomitant dans le traitement du glioblastome nouvellement diagnostiqué -FR Institution: Information not provided - FR

SonoFIRST: Multisite Open-label Randomized Phase II Clinical Trial in Newly Diagnosed Glioblastoma Treated by Concurrent Temoradiation and Adjuvant Temozolomide +/- Ultrasound-induced Blood Brain Barrier Opening -FR Institution: Information not provided - FR

A Multi-center Phase II Study With Light Dose Escalation During Intraoperative Photodynamic Therapy of Glioblastoma -FR Institution: Information not provided - FR

STEAM: Study of TG02 in Elderly Newly Diagnosed or Adult Relapsed Patients With Anaplastic Astrocytoma or Glioblastoma: A Phase Ib Study-FR CHRU de Lille

REGAL: Etude de Phase III du Recentin dans les glioblastomes en récidive CHU Paris Seine-Saint-Denis - Hôpital Avicenne Service de Neurologie

Angiotensin II Receptor Blockers, Steroids and Radiotherapy in Glioblastoma- A Randomized Multicenter Trial (Phase III) - FR CHU Paris Seine-Saint-Denis - Hôpital Avicenne Service de Neurologie

OLA-TMZ-RTE-01 : Etude de phase I/IIa évaluant un traitement concomitant par radiothérapie, olaparib et témozolomide chez les patients atteints d'un gliome de haut grade non résécable Centre François Baclesse Neuro-oncologie

A Phase III Trial of Marizomib in Combination With Standard Temozolomide-based Radiochemotherapy Versus Standard Temozolomide-based Radiochemotherapy Alone in Patients With Newly Diagnosed Glioblastoma-FR Institut de Cancérologie de l'Ouest (ICO) - site René Gauducheau

Vaccination With Autologous Dendritic Cells Loaded With Autologous Tumour Homogenate in Glioblastoma: a Phase II Study IRST - Istituto Scientifico Romagnolo per lo studio e la cura dei Tumori Dipartimento di Oncologia ed Ematologia Clinica e Sperimentale

Repurposing the Antipsychotic Drug Chlorpromazine as a Therapeutic Agent in the Combined Treatment of Newly Diagnosed Glioblastoma Multiforme Istituti Fisioterapici Ospitalieri - Istituto Nazionale Tumori Regina Elena Dipartimento per lo Sviluppo dei Programmi Terapeutici

The STELLAR Study: A Phase II/III Study of High-dose, Intermittent Sunitinib in Patients With Recurrent Glioblastoma Multiforme Amsterdam UMC, locatie VUmc Afdeling Medische Oncologie

STING: Comparing a Treatment Strategy With Levetiracetam Versus Treatment With Valproic Acid in Glioma Patients With a First Seizure (phase IV) LUMC - Leids Universitair Medisch Centrum Afdeling Neurologie

Temozolomide and Radiation Therapy With or Without Vatalanib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme Erasmus MC - Erasmus Medisch Centrum Afdeling Neuro-Oncologie

Phase 3b Study for Management of Ocular Side Effects in Subjects With EGFR-amplified Glioblastoma Receiving Depatuxizumab Mafodotin (ABT-414)-GB Kings College School of Medicine Guy's and St Thomas NHS Foundation Trust

RESDEX - Restrictive Use of Dexamethasone in Glioblastoma Universitätsspital Inselspital Universitätsklinik für Neurochirurgie

A Study to Evaluate the Safety and Efficacy of the Tumor-targeting Human Antibody-cytokine Fusion Protein L19TNF Plus Lomustine in Patients With Glioblastoma at First Progression UniversitätsSpital Zürich Neuromuskuläres Zentrum Zürich (NMZ)

GLUGLIO: A Phase Ib/II Randomized, Open Label Drug Repurposing Trial of Glutamate Signaling Inhibitors in Combination With Chemoradiotherapy in Patients With Newly Diagnosed Glioblastoma Universitätspital Zürich University Hospital Zurich

A Phase 2 clinical study of pomalidomide (CC-4047) monotherapy for children and young adults with recurrent or progressive primary brain tumors. -GB Institution: Information not provided - CH

SonoFIRST: Multisite Open-label Randomized Phase II Clinical Trial in Newly Diagnosed Glioblastoma Treated by Concurrent Temoradiation and Adjuvant Temozolomide +/- Ultrasound-induced Blood Brain Barrier Opening - CH Centre Hospitalier Universitaire Vaudois CHUV Unité de Neuro-oncologie

INFORM2 NivEnt: exploratory multinational phase I/II combination study of Nivolumab and Entinostat in children and adolescents with refractory high-risk malignancies-DE Deutsches Krebsforschungszentrum Klinische Kooperationseinheit Pädiatrische Onkologie

INFORM2 NivEnt: exploratory multinational phase I/II combination study of Nivolumab and Entinostat in children and adolescents with refractory high-risk malignancies-DE Universitätsklinikum Regensburg Abteilung für Pädiatrische Hämatologie, Onkologie und Stammzelltransplantation

INFORM2 NivEnt: exploratory multinational phase I/II combination study of Nivolumab and Entinostat in children and adolescents with refractory high-risk malignancies-DE Universitätsklinikum Essen Klinik für Kinderheilkunde III

HIT-HGG-2013: International cooperative Phase III trial of the HIT-HGG study group for the treatment of high grade glioma, diffuse intrinsic pontine glioma, and gliomatosis cerebri in children and adolescents < 18 years - AT Institution: Information not provided - AT

A Pilot and Surgical Study of Larotrectinib for Treatment of Children With Newly-Diagnosed High-Grade Glioma With NTRK Fusion (Phase 1) - AT Institution: Information not provided - AT

INFORM2 NivEnt: Exploratory Multinational Phase I/II Combination Study of Nivolumab and Entinostat in Children and Adolescents With Refractory High-risk Malignancies - AT St. Anna Kinderspital Zentrum für Kinder- und Jugendheilkunde

Phase I/II multicenter study to assess efficacy and safety of ribociclib (LEE011) in combination with topotecan and temozolomide (TOTEM) in pediatric patients with relapsed or refractory neuroblastoma and other solid tumors -ES Institution: Information not provided - ES

Phase II, open label, monocentric, uncontrolled, non randomized clinical trial on Sodium Fluorescein for Surgery of High Grade Gliomas Fondazione IRCCS Istituto Neurologico "Carlo Besta" UOC Neurochirurgia 2 - Neurochirurgia Vascolare

A Phase II, multicenter, randomized, double-blind study of LY2157299 monohydrate monotherapy or LY2157299 monohydrate Plus Lomustine therapy compared to Lomustine monotherapy in patients with recurrent Glioblastoma - DE
Neurologische Universitätsklinik Heidelberg

Abteilung für Neuroonkologie

NOA-20/Improvement of functional outcome for patients with newly diagnosed grade II or III glioma with co-deletion of 1p/19q - IMPROVE CODEL
Neurologische Universitätsklinik Heidelberg

Abteilung für Neuroonkologie

An open-label, Phase I/II multicenter clinical trial of VXM01 in combination with avelumab in patients with progressive glioblastoma following standard treatment with or without second surgery
Neurologische Universitätsklinik Heidelberg

Abteilung für Neuroonkologie

GERAS: Effect of Timing of Tumor-Treating Fields Plus Short-Course Radiation in Elderly Patients With Glioblastoma
Neurologische Universitätsklinik Heidelberg

Klinik für Radioonkologie und Strahlentherapie

Evaluation of the Feasibility of PD L 506 for Stereotactic Interstitial Photodynamic Therapy (iPDT) in Adult Patients With Newly Diagnosed Supratentorial IDH Wild-type Glioblastoma
LMU Klinikum der Universität München - Campus Großhadern

Neurochirurgische Klinik und Poliklinik

CAR2BRAIN: Single Center, Open Label, Phase I Study of Intracranial Injection of NK-92/5.28.z (HER2.taNK) Cells in Patients With Recurrent HER2-positive Glioblastoma
Institution: Information not provided - DE

Autologous Dendritic Cells and Metronomic Cyclophosphamide for Relapsed High-Grade Gliomas in Children and Adolescents
Universitätsmedizin Göttingen

Klinik für Kinder- und Jugendmedizin

GLORIA: Single-arm, Dose-Escalation, Phase 1/2 Study of Olaptesed Pegol (NOX-A12) in Combination with Irradiation in Inoperable or Partially Resected First-line Glioblastoma Patients with Unmethylated MGMT Promoter
Universitätsklinikum Bonn (AöR)

Klinik und Poliklinik für Neurologie

MecMeth: Phase I/II study of meclofenamate/temozolomide combination therapy for relapsed MGMT promoter-methylated glioblastoma.
Universitätsklinikum Bonn (AöR)

Klinik und Poliklinik für Neurologie

Phase II trial of vaccination with lysate-loaded, mature dendritic cells integrated into standard radiochemotherapy in newly diagnosed glioblastoma -DE-
Universitätsklinikum Düsseldorf

Klinik für Neurochirurgie

GLORIA: Single-arm, Dose-Escalation, Phase 1/2 Study of Olaptesed Pegol (NOX-A12) in Combination with Irradiation in Inoperable or Partially Resected First-line Glioblastoma Patients with Unmethylated MGMT Promoter
Universitätsklinikum Essen

Klinik für Neurologie

PriCoTTF - PriCoTTF Study: A phase I/II study with TTFields before and during radiotherapy in newly diagnosed glioblastoma
Westdeutsches Tumorzentrum Essen (WTZ)

Klinik für Innere Medizin (Tumorforschung)

MIRAGE: A Phase III Trial of Marizomib in Combination With Standard Temozolomide-based Radiochemotherapy Versus Standard Temozolomide-based Radiochemotherapy Alone in Patients With Newly Diagnosed Glioblastoma - AT
Institution: Information not provided - AT

TRIDENT EF-32: Pivotal, Randomized, Open-Label Study of Optune® (Tumor Treating Fields, 200kHz) Concomitant With Radiation Therapy and Temozolomide for the Treatment of Newly Diagnosed Glioblastoma - AT
Institution: Information not provided - AT

GBM AGILE: Global Adaptive Trial Master Protocol: An International, Seamless Phase II/III Response Adaptive Randomization Platform Trial Designed To Evaluate Multiple Regimens In Newly Diagnosed and Recurrent GBM - AT
Institution: Information not provided - AT

ADDIT-GLIO: Adjuvant Dendritic-Cell Immunotherapy Plus Temozolomide Following Surgery and Chemoradiation in Patients With Newly Diagnosed Glioblastoma
Antwerp University Hospital - UZA

Antwerp University Hospital

DOSINDYGO: Etude de Phase II multicentrique avec escalade de dose-lumière, de la thérapie photodynamique peropératoire du glioblastome - BE
Cliniques Universitaires de Bruxelles - Hôpital Erasme

Service de Neurologie

Etude de phase IIb visant à évaluer l'efficacité d'un traitement du glioblastome / gliosarcome par la suppression de la voie PI3K / Akt par rapport à la MK-3475 (Pembrolizumab)
Cliniques universitaires Saint-Luc - UCLouvain

Cliniques Universitaires Saint-Luc

A Randomized Phase II Clinical Trial on the Efficacy of Axitinib as a Monotherapy or in Combination With Lomustine for the Treatment of Patients With Recurrent Glioblastoma
Universitair Ziekenhuis Brussel

NMRC Site UZBrussel

Phase II Clinical Trial on the Combination of Avelumab and Axitinib for the Treatment of Patients With Recurrent Glioblastoma
Universitair Ziekenhuis Brussel

Universitair Ziekenhuis Brussel (UZ Brussel)

SonoFIRST: Multisite Open-label Randomized Phase II Clinical Trial in Newly Diagnosed Glioblastoma Treated by Concurrent Temoradiation and Adjuvant Temozolomide +/- Ultrasound-induced Blood Brain Barrier Opening - BE
UZ Leuven - Campus Gasthuisberg

Dienst Neurochirurgie

A Phase 2 clinical study of pomalidomide (CC-4047) monotherapy for children and young adults with recurrent or progressive primary brain tumors -ES
Institution: Information not provided - ES

A Phase 1b, Open-label, Dose-Finding Study of CC-90010 in Combination With Temozolomide With or Without Radiation Therapy in Subjects With Newly Diagnosed Glioblastoma - ES
Institution: Information not provided - ES

ROSALIE: A MulticenteR, Open-Label, First-in-Human, PhaSe Ib/IIa Trial of EO2401, a Novel Multipeptide Therapeutic VAccine, with and without PD-1 Check Point Inhibitor, FoLlowing Standard Treatment in PatIents with ProgrEssive Glioblastoma - ES
Institution: Information not provided - ES

MIRAGE: A phase III trial of marizomib in combination with standard temozolomide-based radiochemotherapy versus standard temozolomide-based radiochemotherapy alone in patients with newly diagnosed glioblastoma - ES
Institution: Information not provided - ES

A Phase Ib Dose Finding Study Assessing Safety and Activity of [177Lu]Lu-DOTA-TATE in Newly Diagnosed Glioblastoma in Combination With Radiotherapy With or Without Temozolomide and in Recurrent Glioblastoma as Single Agent -ES
Institution: Information not provided - ES

A Phase 1 Study to Investigate the Safety, Pharmacokinetics, and Efficacy of Tinostamustine, a Novel Alkylating and Deacetylase Inhibiting Molecule, as Adjuvant Treatment in Patients with Newly Diagnosed Unmethylated MGMT-promoter Glioblastoma -ES
Institution: Information not provided - ES

INDIGO: A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study of AG-881 in Subjects With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation - ES
Institution: Information not provided - ES

GLINERA: Pilot safety study of neoadjuvant radiotherapy in patients with glioblastoma - ES
Hospital Clínico San Carlos

Servicio de Neurocirugía

GEINOGLAS: Phase Ib/II Multicentric Study Combining Glasdegib with temozolomide in patients with newly diagnosed Glioblastoma, safety and preliminary efficacy for the combination - ES
Hospital Universitario Ramón y Cajal

Servicio de Oncología Médica

A Phase I Study of Cytosine Deaminase-Expressing Neural Stem Cells in Combination With Oral 5-Fluorocytosine and Leucovorin for the Treatment of Recurrent High-Grade Gliomas - US
City of Hope

City of Hope National Medical Center

A Phase 2, Investigator Initiated Study to Determine the Safety and Efficacy of TH-302 in Combination With Bevacizumab for Glioblastoma Following Bevacizumab Failure - US
University of Texas Health Science Center

A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC Versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma
Institution: Information not provided - US

A Phase II, Multi-center, Open-label Study of a Conditionally Replicative Adenovirus (DNX-2401) With Pembrolizumab (KEYTRUDA®) for Recurrent Glioblastoma or Gliosarcoma (CAPTIVE/KEYNOTE-192)
Institution: Information not provided - US

A Phase 2 Trial of High-Dose Ascorbate in Glioblastoma Multiforme
Institution: Information not provided - US

Vaccine Therapy for the Treatment of Newly Diagnosed Glioblastoma Multiforme
Institution: Information not provided - US

Anti-LAG-3 or Urelumab Alone and in Combination With Nivolumab in Treating Patients With Recurrent Glioblastoma
Institution: Information not provided - US

Qualitative, Qualitative, and Functional Studies Over the First Year in Measuring Immune System Response During the First Year of Therapy in Patients With Brain Tumors
Institution: Information not provided - US

Tremelimumab and Durvalumab in Combination or Alone in Treating Patients With Recurrent Malignant Glioma
Institution: Information not provided - US

Bevacizumab and Ascorbic Acid in Patients Treating With Recurrent High Grade Glioma
Institution: Information not provided - US

Cediranib Maleate and Olaparib Compared to Bevacizumab in Treating Patients With Recurrent Glioblastoma
Institution: Information not provided - US

Radiation Therapy Plus Temozolomide and Pembrolizumab With and Without HSPPC-96 in Newly Diagnosed Glioblastoma (GBM)
Institution: Information not provided - US

NU-0129 in Treating Patients With Recurrent Glioblastoma or Gliosarcoma Undergoing Surgery
Institution: Information not provided - US

Pembrolizumab and Standard Therapy in Treating Patients With Glioblastoma
Institution: Information not provided - US

Ferumoxytol MRI in Assessing Response to Pembrolizumab in Patients With Brain Tumors From Melanoma and Glioblastoma
Institution: Information not provided - US

Randomized, Prospective, Multicenter Blinding Singles With Arm A and Arm B Innovative Strategy Strategy Conventional (Phase III) - FR
CHU de Lyon HCL - GH Est-Hôpital Neurologique P. Wertheimer

Service de neurochirurgie tumorale - chirurgie des malformations vasculaires du systéme nerveux

GLYRad : Etude de phase I/II testant l'association du LY2228820 à une radiochimiothérapie avec TMZ concomitant chez des patients présentant un glioblastome nouvellement diagnostiqué
CLCC Jean Perrin

Phase Ib/II Multicenter Study of Buparlisib Plus Carboplatin or Lomustine in Patients With Recurrent Glioblastoma Multiforme (Phase I and II) - FR
Institution: Information not provided - FR

A Phase 2, Multicenter, Open-label Study of BGJ398 in Patients With Recurrent Resectable or Unresectable Glioblastoma (Phase II) - FR
Institution: Information not provided - FR

NANO-GBM: Étude de phase I/II des nanoparticules AGuIX avec radiothérapie plus témozolomide concomitant dans le traitement du glioblastome nouvellement diagnostiqué -FR
Institution: Information not provided - FR

SonoFIRST: Multisite Open-label Randomized Phase II Clinical Trial in Newly Diagnosed Glioblastoma Treated by Concurrent Temoradiation and Adjuvant Temozolomide +/- Ultrasound-induced Blood Brain Barrier Opening -FR
Institution: Information not provided - FR

A Multi-center Phase II Study With Light Dose Escalation During Intraoperative Photodynamic Therapy of Glioblastoma -FR
Institution: Information not provided - FR

STEAM: Study of TG02 in Elderly Newly Diagnosed or Adult Relapsed Patients With Anaplastic Astrocytoma or Glioblastoma: A Phase Ib Study-FR
CHRU de Lille

REGAL: Etude de Phase III du Recentin dans les glioblastomes en récidive
CHU Paris Seine-Saint-Denis - Hôpital Avicenne

Service de Neurologie

Angiotensin II Receptor Blockers, Steroids and Radiotherapy in Glioblastoma- A Randomized Multicenter Trial (Phase III) - FR
CHU Paris Seine-Saint-Denis - Hôpital Avicenne

Service de Neurologie

OLA-TMZ-RTE-01 : Etude de phase I/IIa évaluant un traitement concomitant par radiothérapie, olaparib et témozolomide chez les patients atteints d'un gliome de haut grade non résécable
Centre François Baclesse

Neuro-oncologie

A Phase III Trial of Marizomib in Combination With Standard Temozolomide-based Radiochemotherapy Versus Standard Temozolomide-based Radiochemotherapy Alone in Patients With Newly Diagnosed Glioblastoma-FR
Institut de Cancérologie de l'Ouest (ICO) - site René Gauducheau

Vaccination With Autologous Dendritic Cells Loaded With Autologous Tumour Homogenate in Glioblastoma: a Phase II Study
IRST - Istituto Scientifico Romagnolo per lo studio e la cura dei Tumori

Dipartimento di Oncologia ed Ematologia Clinica e Sperimentale

Repurposing the Antipsychotic Drug Chlorpromazine as a Therapeutic Agent in the Combined Treatment of Newly Diagnosed Glioblastoma Multiforme
Istituti Fisioterapici Ospitalieri - Istituto Nazionale Tumori Regina Elena

Dipartimento per lo Sviluppo dei Programmi Terapeutici

The STELLAR Study: A Phase II/III Study of High-dose, Intermittent Sunitinib in Patients With Recurrent Glioblastoma Multiforme
Amsterdam UMC, locatie VUmc

Afdeling Medische Oncologie

STING: Comparing a Treatment Strategy With Levetiracetam Versus Treatment With Valproic Acid in Glioma Patients With a First Seizure (phase IV)
LUMC - Leids Universitair Medisch Centrum

Afdeling Neurologie

Temozolomide and Radiation Therapy With or Without Vatalanib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Erasmus MC - Erasmus Medisch Centrum

Afdeling Neuro-Oncologie

Phase 3b Study for Management of Ocular Side Effects in Subjects With EGFR-amplified Glioblastoma Receiving Depatuxizumab Mafodotin (ABT-414)-GB
Kings College School of Medicine

Guy's and St Thomas NHS Foundation Trust

RESDEX - Restrictive Use of Dexamethasone in Glioblastoma
Universitätsspital Inselspital

Universitätsklinik für Neurochirurgie

A Study to Evaluate the Safety and Efficacy of the Tumor-targeting Human Antibody-cytokine Fusion Protein L19TNF Plus Lomustine in Patients With Glioblastoma at First Progression
UniversitätsSpital Zürich

Neuromuskuläres Zentrum Zürich (NMZ)

GLUGLIO: A Phase Ib/II Randomized, Open Label Drug Repurposing Trial of Glutamate Signaling Inhibitors in Combination With Chemoradiotherapy in Patients With Newly Diagnosed Glioblastoma
Universitätspital Zürich

University Hospital Zurich

A Phase 2 clinical study of pomalidomide (CC-4047) monotherapy for children and young adults with recurrent or progressive primary brain tumors. -GB
Institution: Information not provided - CH

SonoFIRST: Multisite Open-label Randomized Phase II Clinical Trial in Newly Diagnosed Glioblastoma Treated by Concurrent Temoradiation and Adjuvant Temozolomide +/- Ultrasound-induced Blood Brain Barrier Opening - CH
Centre Hospitalier Universitaire Vaudois CHUV

Unité de Neuro-oncologie

INFORM2 NivEnt: exploratory multinational phase I/II combination study of Nivolumab and Entinostat in children and adolescents with refractory high-risk malignancies-DE
Deutsches Krebsforschungszentrum

Klinische Kooperationseinheit Pädiatrische Onkologie

INFORM2 NivEnt: exploratory multinational phase I/II combination study of Nivolumab and Entinostat in children and adolescents with refractory high-risk malignancies-DE
Universitätsklinikum Regensburg

Abteilung für Pädiatrische Hämatologie, Onkologie und Stammzelltransplantation

INFORM2 NivEnt: exploratory multinational phase I/II combination study of Nivolumab and Entinostat in children and adolescents with refractory high-risk malignancies-DE
Universitätsklinikum Essen

Klinik für Kinderheilkunde III

HIT-HGG-2013: International cooperative Phase III trial of the HIT-HGG study group for the treatment of high grade glioma, diffuse intrinsic pontine glioma, and gliomatosis cerebri in children and adolescents < 18 years - AT
Institution: Information not provided - AT

A Pilot and Surgical Study of Larotrectinib for Treatment of Children With Newly-Diagnosed High-Grade Glioma With NTRK Fusion (Phase 1) - AT
Institution: Information not provided - AT

INFORM2 NivEnt: Exploratory Multinational Phase I/II Combination Study of Nivolumab and Entinostat in Children and Adolescents With Refractory High-risk Malignancies - AT
St. Anna Kinderspital

Zentrum für Kinder- und Jugendheilkunde

Phase I/II multicenter study to assess efficacy and safety of ribociclib (LEE011) in combination with topotecan and temozolomide (TOTEM) in pediatric patients with relapsed or refractory neuroblastoma and other solid tumors -ES
Institution: Information not provided - ES

Phase II, open label, monocentric, uncontrolled, non randomized clinical trial on Sodium Fluorescein for Surgery of High Grade Gliomas
Fondazione IRCCS Istituto Neurologico "Carlo Besta"

UOC Neurochirurgia 2 - Neurochirurgia Vascolare

PARC: Phase I/II Study Evaluating the Safety and Activity of Pegylated Recombinant Human Arginase (BCT-100) in Relapsed/Refractory Cancers of Children and Young Adults -GB
University of Birmingham

University of Birmingham HQ

Does giving patients, who have never had a seizure, an anti-epileptic drug before surgery help prevent them from developing seizures?
Institution: Information not provided - GB

Diagnostic Performance of Fluorescein as an Intraoperative Brain Tumor Biomarker: Correlation With Preoperative MR, ALA-induced PpIX Fluorescence, and Histopathology
Institution: Information not provided - US

PVSRIPO With/Without Lomustine
Institution: Information not provided - US